Role of polymorphic Fc receptor Fcγ/RIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31)

Transplantation

Volumn 63, Issue 1, 1997, Pages 106-112

  Tax, Wil J M ^a   Tamboer, Wim P M ^a   Jacobs, Cor W M ^a   Frenken, Leon A M ^a   Koene, Robert A P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 6; OKT 3; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; FEVER; GENETIC POLYMORPHISM; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CYTOKINES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; RECEPTORS, IGG;

EID: 0031035244     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701150-00020     Document Type: Article

References (28)

1. Thistlethwaite JRJ, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112.
2. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
3. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697.
4. Tax WJM, Willems HW, Reekers PPM, Capel PJA, Koene RAP. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature 1983; 304: 445.
5. Tax WJM, Hermes FFM, Willems RW, Capel PJA, Koene RAP. Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation. J Immunol 1984; 133: 1185.
6. van de Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991; 49: 511.
7. Frenken LAM, Koene RAP, Tax WJM. The role of antibody isotype in IFN-γ and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 1991; 51: 881.
8. Tax WJM, Holtrop S, Koene RAP. Clinical implications of the polymorphic interaction of murine IgG2b and IgG1 with human Fc receptors. Transplant Immunol 1993; 1: 250.
9. Tax WJM, Leeuwenberg HFM, Willems HW, Capel PJA, Koene RAP. Monoclonal antibodies reactive with OKT3 antigen or OKT8 antigen. In: Bernard A et al., eds. Leucocyte typing I, Berlin: Springer Verlag, 1984: 721.
10. Spits H, Borst J, Tax WJM, Capel PJA, Terhorst C, de Vries JE. Characteristics of a monoclonal antibody (WT-31) that recognizes a common epitope on the human T cell receptor for antigen. J Immunol 1985; 135: 1922.
11. Jiskoot W, van Hertrooij JJ, Hoven AM, et al. Preparation of clinical grade monoclonal antibodies from serum-containing cell culture supernatants. J Immunol Methods 1991; 138: 273.
12. Osborne JM, Chacko GW, Brandt JT, Anderson C. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. J Immunol Methods 1994; 173: 207.
13. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117.
14. Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25: 1492.
15. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625.
16. Chatenoud L, Legendre C, Kurrle R, Kreis H, Bach JF. Absence of clinical symptoms following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. Transplantation 1993; 55: 443.
17. Parlevliet KJ, ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93: 2519.
18. Matthys P, Dillen C, Proost P, Heremans H, Van-Damme J, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol 1993; 23: 2209.
19. Wee SL, Colvin RB, Phelan JM, et al. Fc-receptor for mouse IgG1 (Fc gamma RII) and antibody-mediated cell clearance in patients treated with Leu2a antibody. Transplantation 1989; 48: 1012.
20. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Transplantation 1995; 60: 828.
21. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12: 979.
22. Tax WJM, van der Heijden HMW, Willems HW, et al. Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc 1987; 19: 1905.
23. Bemelman FJ, Parlevliet KJ, Schellekens PT, Surachno S, van Royen EA, ten Berge RJ. Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependent. Transplant Immunol 1994; 2: 47.
24. Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab′)2 fragments-retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 1991; 52: 354.
25. Yong KL, Rowles PM, Patterson KG, Linch DC. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood 1992; 80: 1565.
26. Leeuwenberg JFM, Spits H, Tax WJM, Capel PJA. Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. J Immunol 1985; 134: 3770.
27. Allebes W, Knops R, Herold M, Huber C, Haanen C, Capel P. Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine production. Leuk Res 1991; 15: 215.
28. Alegre ML, Collins AM, Pulito VL, et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 1992; 148: 3461.